Get the Stockscreener App
32.96
3.57%
-1.22
After Hours:
33.61
0.65
+1.97%
Stoke Therapeutics Inc stock is traded at $32.96, with a volume of 337.29K.
It is down -3.57% in the last 24 hours and up +0.67% over the past month.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
See More
Previous Close:
$34.18
Open:
$34.49
24h Volume:
337.29K
Relative Volume:
0.48
Market Cap:
$1.95B
Revenue:
$184.42M
Net Income/Loss:
$-6.89M
P/E Ratio:
-221.95
EPS:
-0.1485
Net Cash Flow:
$44.92M
1W Performance:
-1.11%
1M Performance:
+0.67%
6M Performance:
+44.43%
1Y Performance:
+239.79%
1-Day Range:
$32.20
$35.24
1-Week Range:
$32.08
$35.24
52-Week Range:
$8.30
$40.22
Stoke Therapeutics Inc Stock (STOK) Company Profile
Name
Stoke Therapeutics Inc
Sector
Industry
Phone
781-430-8200
Address
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
32.96 | 2.02B | 184.42M | -6.89M | 44.92M | -0.1485 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Feb-05-26 | Initiated | Guggenheim | Buy |
| Jan-05-26 | Resumed | Chardan Capital Markets | Buy |
| Jul-18-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Mar-26-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Jul-25-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| May-01-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Apr-26-23 | Resumed | Canaccord Genuity | Buy |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
| Oct-24-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jan-31-22 | Initiated | Jefferies | Buy |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Nov-22-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-21 | Initiated | UBS | Neutral |
| May-10-21 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Dec-11-20 | Reiterated | Needham | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Sep-29-20 | Initiated | Needham | Buy |
| Dec-18-19 | Initiated | Wedbush | Outperform |
| Nov-12-19 | Initiated | BTIG Research | Buy |
| Oct-25-19 | Initiated | H.C. Wainwright | Buy |
| Jul-15-19 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Credit Suisse | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
View All
Stoke Therapeutics Inc Stock (STOK) Latest News
Insider Sell Alert: Barry Ticho Sells Shares of Stoke Therapeuti - GuruFocus
Stoke Therapeutics (STOK) CMO sells 2,243 shares in open-market trade - Stock Titan
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Quantisnow
Hussman Strategic Advisors Inc. Takes Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics (STOK) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Baruch S. Ticho sells STOK shares under 10b5-1 (STOK) - Stock Titan
Stoke Therapeutics: Zorevunersen Has Disease-Modifying Potential In Dravet Syndrome (STOK) - Seeking Alpha
Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates - BioSpace
Epilepsy Pipeline Grows as 75+ Pharma Companies Advance 90+ - openPR.com
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
(STOK) Volatility Zones as Tactical Triggers - Stock Traders Daily
Stoke Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
STOK Should I Buy - Intellectia AI
[ARS] Stoke Therapeutics, Inc. SEC Filing - Stock Titan
Executive pay, board elections and new auditor at Stoke Therapeutics (NASDAQ: STOK) - Stock Titan
De-Risked Phase 3 Design and Durable Efficacy Support Buy Rating on Stoke Therapeutics’ Zorevunersen - TipRanks
Stoke Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Needham Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $40 - Moomoo
STOK: Zorevunersen shows sustained efficacy and cognitive gains, with phase III readout expected mid-2027 - TradingView
Price-Driven Insight from (STOK) for Rule-Based Strategy - Stock Traders Daily
Baillie Gifford & Co. Purchases New Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Fed Meeting: Is Stoke Therapeutics Inc a strong candidate for buy and hold2026 Bull vs Bear & Weekly Market Pulse Alerts - baoquankhu1.vn
Treasury Yields: Is Stoke Therapeutics Inc a cyclical or defensive stock2026 Year in Review & Verified Momentum Stock Ideas - baoquankhu1.vn
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference - BioSpace
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress - NTB Kommunikasjon
Wolfe Research Initiates Coverage on Stoke Therapeutics (STOK) w - GuruFocus
Stoke Therapeutics Appoints Clare Kahn, Ph.D. to Board and Advances Zorevunersen for Dravet Syndrome Treatment - Minichart
Stoke Therapeutics Appoints Clare Kahn to Board - citybiz
Stoke Therapeutics : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
Stoke Therapeutics (STOK) director receives 30,782-share stock option grant - Stock Titan
Stoke Therapeutics (STOK) director Kahn Clare submits initial Form 3 insider report - Stock Titan
Stoke Therapeutics appoints Clare Kahn to board of directors By Investing.com - Investing.com India
Stoke Therapeutics Adds Veteran Leader to Board, R&D Oversight - TipRanks
Stoke Therapeutics appoints Clare Kahn to board of directors - Investing.com
Clare Kahn joins Stoke Therapeutics (Nasdaq: STOK) board, receives option grant - Stock Titan
Stoke Therapeutics, Inc. Appoints Clare Kahn as Directors and to Serve on Nominating and Corporate Governance Committee and as Chairperson of the Research and Development Committee of the Board, Effective April 3, 2026 - marketscreener.com
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors - Yahoo Finance
Trading Recap: Can Stoke Therapeutics Inc grow without external fundingQuarterly Market Summary & Technical Entry and Exit Tips - baoquankhu1.vn
Stoke Therapeutics Auditor Switch Puts Biotech Governance In Focus - Yahoo Finance
Should I Buy Stoke Therapeutics (STOK) Stock in 2026 | Price at $32.93, Up 0.57%Social Trading - Cổng thông tin điện tử Tỉnh Sơn La
Growth Value: What is the earnings history of Stoke Therapeutics Inc2026 Major Catalysts & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Stoke Therapeutics (STOK) CMO sells 1,838 shares in planned open-market trade - Stock Titan
(STOK) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Stoke Therapeutics (STOK) Price Target Increased by 16.51% to 28.79 - MSN
Insider sells shares under 10b5-1 — STOK (NASDAQ: STOK) discloses trades - Stock Titan
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
STOK Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Stoke Therapeutics (STOK) price target increased by 12.11% to 43.96 - MSN
Stoke Therapeutics Hits Day High with 7.98% Surge in Strong Intraday Performance - Markets Mojo
Stoke Therapeutics Stock Up 340% as Chair Sells $174K in Shares - AOL.com
Stoke Therapeutics, Inc. Files 8-K Announcing Change in Certifying Accountant – March 2026 - minichart.com.sg
Stoke Therapeutics Inc Stock (STOK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):